The Farber Center for Radiation Oncology
Presents
ROCKS AGAINST CANCER
A Fundraising Event for Entertainment Industry Foundation
benefiting EIF Cancer Programs.
Thursday, Sept 16th 7pm to 11pm
BLACK TIE ROCK & ROLL STYLE!
To purchase tickets or donate click here: Rocks Against Cancer Tickets
The event will take place at the Angel Orensanz Foundation for the Arts, situated on 172 Norfolk Street in the former Ansche Chesed Synagogue, the venue boasts superbly maintained mid-19th century architecture.
The lounge-style space will feature cocktails and food as well as performances by The Rotten Hill Gang, a six-piece band from London fronted by Mick Jones of The Clash. Eclectic Method featuring London natives Jonny Wilson, Ian Edgar and Geoff Gamlen – who helped pioneer the emerging art of audio-visual mixing since first cutting U2’s Mysterious Ways music video with the Beastie Boys’ Intergalactic as an experiment back in 2002 will close out the night.
The event also includes a silent auction of jewelry by Stephen Webster—three-time winner of the “British Luxury Jeweller of the Year” award and 2008 winner of “UK Jewellery Brand of the Year”—including specially designed bracelets supporting the fight against cancer with net proceeds benefiting EIF’s Cancer programs. Webster is widely known as the jeweler to the stars; his celebrity client list includes Madonna, Elizabeth Taylor, Jennifer Lopez, Kim Cattrall, and Christina Aguilera among others.
Some of EIF’s cancer programs include: Stand Up To Cancer (SU2C), Woman’s Cancer Research Fund, Brains on Bikes, Right Action for Woman, and the National Colorectal Research Alliance
If you are arriving from out of town please contact the Smyth – part of the Thompson Hotels at 85 West Broadway phone: 212.587.7000. We have reserved rooms at a special rate under the group name Rocks Against Cancer.
A special thanks to our current sponsors at the time this blog went out: Stephen Webster, Matthew Robbins Desings, Svendka, Warren Tricomi, and Elekta Inc.
MDV3100 is an investigational therapy in clinical development for the treatment of advanced prostate cancer. The first triple-acting, oral anti-androgen, MDV3100 has been shown in preclinical studies to provide more compIete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions. read more at:
a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.
I came a across a group that is called Us TOO. Us TOO is a grassroots organization started in 1990 by prostate cancer survivors to serve prostate cancer survivors, their spouses/partners and families. They are a 501(c)(3) not-for-profit charitable organization dedicated to communicating timely and reliable information enabling informed choices regarding detection and treatment of prostate cancer.
